Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
At Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu, research in Hemic and Lymphatic Diseases focuses on blood cancers and related disorders, with studies aimed at improving treatment options, response rates, and patient outcomes.
- Studies in acute myeloid leukaemia are exploring more effective, personalized treatment strategies for newly diagnosed patients.
- Trials in myelodysplastic syndrome are evaluating new ways to improve anemia control and reduce the need for transfusions.
- Research in hemophilia A and hemophilia B is assessing preventive therapies to better manage bleeding risk.
The site’s hematology team is contributing to research that aims to refine care for both malignant and non-malignant blood disorders.
Neoplasms
The oncology portfolio at this hospital includes trials for aggressive and relapsed cancers, especially large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and classical Hodgkin lymphoma, with a strong emphasis on testing newer treatment approaches.
- Studies in diffuse large B-cell lymphoma are comparing emerging therapies with standard care to improve disease control.
- Trials in relapsed or refractory lymphomas are examining options for patients whose disease has returned or resisted prior treatment.
- Research in follicular lymphoma is evaluating novel combinations to improve long-term remission and response.
- Work in classical Hodgkin lymphoma is focused on finding more effective choices after earlier therapies have failed.
Overall, the site is active in testing new therapies for hematologic malignancies and in comparing them with established treatment standards.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 165 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 157 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 22 by active trials.
- 1Medical University Of Gdansk4active
lock +21 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Agencja Badań Medycznych5trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
lock Showing 1 of 76 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2) | Apcintex Limited | Phase II | Not Recruiting | Nov 2023 | Jan 2025 |
IMP list
lock Showing 1 of 165 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 12 | Unknown | 2017-07-14 | 2026-02-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.